Slovenian experience with erenumab

Background and aims: Erenumab is novel monoclonal antibody against canonical CGRP receptor for prophylaxis of migraine. In Slovenia its use is approved for the treatment of patients with 4 or more monthly migraine days and 2 or more failed prophylactic drugs. Methods: We are prospectively monitoring 41 patients that have received erenumab from December 2018. We are recording number of monthly migraine headache days (MMD) and number of monthly acute antimigraine tablets (MMT) as well as side effects. Results: These are interim results of a one-year study. Mean age of patients is 44.4±10.4 years and there are 35 (85%) women. In patients treated at least 3 months (N=38) baseline MMD was 9.1±0.7 and was reduced to 4.7±0.4 for 3-month period (p<0.001). In patients treated at least 6 months (N=28) baseline MMD was 11.3±2.8 and was reduced to 4.2±0.6 for 6-month period (p<0.001). Similar results were observed for MMT (box plots 1 and 2). The most common side effects were constipation (41%), reaction at the site of applicaton (17%) and fatigue (12%). Other reported side effects were signs upper respiratory tract infection, muscle cramps, flue-like symptoms and anxiety. There were no serious side effects noted. Conclusion: In our experince erenumab is effective and safe for reducing migraine burden in patients with 2 or more failed prophylactic treatments. This is in line with previously published data from clinical randomized studies. (Figure Presented) .